Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Fuente:
Redalyc
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Universidad del Valle
2021
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1876462870263234560 |
|---|---|
| author | Adriana Linares Ballesteros |
| author_facet | Adriana Linares Ballesteros |
| contents | Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study Adriana Linares Ballesteros Roy Sanguino Lobo Juan Camilo Villada Valencia Oscar Arévalo Leal Diana Constanza Plazas Hernández Nelson Aponte Barrios Iván Perdomo Ramírez Medicina Child leukemia drug therapy anthracyclines echocardiography Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity.Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy.Methods: A prospective descriptive study of patients >1 y and <18 years diagnosed with acute leukemia. Assessed with electrocardiograma, echocardiography, and blood biomarkers at diagnosis and during the follow-up.Results: 94 patients with acute lymphoblastic leukemia and 18 with acute myeloid leukemia were included. 20 patients (17.9%) developed early-onset cardiotoxicity. Statistically significant data was seen after anthracycline dose >150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity.Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction. 2021 artículo científico 0120-8322 https://www.redalyc.org/articulo.oa?id=28366572004 https://www.redalyc.org/journal/283/28366572004/ https://www.redalyc.org/journal/283/28366572004/html/ https://www.redalyc.org/journal/283/28366572004/28366572004.epub https://www.redalyc.org/journal/283/28366572004/movil 10.25100/cm.v52i1.4542 en http://www.redalyc.org/revista.oa?id=283 Colombia Médica application/pdf Universidad del Valle Colombia Médica (Colombia) Num.1 Vol.52 |
| format | Artículo científico |
| id | redalyc_28366572004 |
| institution | Redalyc |
| language | en |
| publishDate | 2021 |
| publisher | Universidad del Valle |
| spellingShingle | Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study Adriana Linares Ballesteros Medicina Child leukemia drug therapy anthracyclines echocardiography Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study Adriana Linares Ballesteros Roy Sanguino Lobo Juan Camilo Villada Valencia Oscar Arévalo Leal Diana Constanza Plazas Hernández Nelson Aponte Barrios Iván Perdomo Ramírez Medicina Child leukemia drug therapy anthracyclines echocardiography Background: Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity.Objective: To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy.Methods: A prospective descriptive study of patients >1 y and <18 years diagnosed with acute leukemia. Assessed with electrocardiograma, echocardiography, and blood biomarkers at diagnosis and during the follow-up.Results: 94 patients with acute lymphoblastic leukemia and 18 with acute myeloid leukemia were included. 20 patients (17.9%) developed early-onset cardiotoxicity. Statistically significant data was seen after anthracycline dose >150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity.Conclusions: Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction. 2021 artículo científico 0120-8322 https://www.redalyc.org/articulo.oa?id=28366572004 https://www.redalyc.org/journal/283/28366572004/ https://www.redalyc.org/journal/283/28366572004/html/ https://www.redalyc.org/journal/283/28366572004/28366572004.epub https://www.redalyc.org/journal/283/28366572004/movil 10.25100/cm.v52i1.4542 en http://www.redalyc.org/revista.oa?id=283 Colombia Médica application/pdf Universidad del Valle Colombia Médica (Colombia) Num.1 Vol.52 |
| title | Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study |
| topic | Medicina Child leukemia drug therapy anthracyclines echocardiography |
| url | https://www.redalyc.org/articulo.oa?id=28366572004 https://www.redalyc.org/journal/283/28366572004/ https://www.redalyc.org/journal/283/28366572004/html/ https://www.redalyc.org/journal/283/28366572004/28366572004.epub https://www.redalyc.org/journal/283/28366572004/movil |